Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.

Yoda RA, Marxen T, Longo L, Ene C, Wirsching HG, Keene CD, Holland EC, Cimino PJ.

J Neuropathol Exp Neurol. 2019 Aug 14. pii: nlz082. doi: 10.1093/jnen/nlz082. [Epub ahead of print]

PMID:
31529048
2.

Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers.

Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT.

Nat Commun. 2019 Sep 3;10(1):3974. doi: 10.1038/s41467-019-11911-5.

3.

Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma dependends on MMP9.

Wirsching HG, Arora S, Zhang H, Szulzewsky F, Cimino PJ, Quéva C, Houghton AM, Glorioso JC, Weller M, Holland EC.

Neuro Oncol. 2019 Aug 15. pii: noz145. doi: 10.1093/neuonc/noz145. [Epub ahead of print] No abstract available.

PMID:
31412117
4.

IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma.

Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT.

Nat Cell Biol. 2019 Aug;21(8):1003-1014. doi: 10.1038/s41556-019-0363-9. Epub 2019 Aug 1.

PMID:
31371825
5.

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.

Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB.

J Neurooncol. 2019 Sep;144(2):403-407. doi: 10.1007/s11060-019-03243-7. Epub 2019 Jul 19.

PMID:
31325145
6.

Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.

Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, Kumasaka D, Pierce RH, Weller M, Finer M, Quéva C, Glorioso JC, Houghton AM, Holland EC.

JCI Insight. 2019 Jul 11;4(13). pii: 128217. doi: 10.1172/jci.insight.128217. eCollection 2019 Jul 11.

7.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. No abstract available.

PMID:
31150022
8.

The molecular landscape of adult diffuse gliomas and relevance to clinical trials.

Cimino PJ, Holland EC.

Oncotarget. 2019 Mar 5;10(19):1758-1759. doi: 10.18632/oncotarget.26750. eCollection 2019 Mar 5. No abstract available.

9.

Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.

Cimino PJ, Holland EC.

Neuro Oncol. 2019 Jun 10;21(6):819-821. doi: 10.1093/neuonc/noz052. No abstract available.

PMID:
30918961
10.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. Review.

11.

Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years.

Ene CI, Macomber MW, Barber JK, Ferreira MJ, Ellenbogen RG, Holland EC, Rockhill JK, Silbergeld DL, Halasz LM.

Neurosurgery. 2019 Aug 1;85(2):E322-E331. doi: 10.1093/neuros/nyy520.

PMID:
30576476
12.

Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity.

Wallmann T, Zhang XM, Wallerius M, Bolin S, Joly AL, Sobocki C, Leiss L, Jiang Y, Bergh J, Holland EC, Enger PØ, Andersson J, Swartling FJ, Miletic H, Uhrbom L, Harris RA, Rolny C.

iScience. 2018 Nov 30;9:71-83. doi: 10.1016/j.isci.2018.10.011. Epub 2018 Oct 16.

13.

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M.

Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26. No abstract available.

PMID:
30259105
14.

Analysis and visualization of linked molecular and clinical cancer data by using Oncoscape.

McFerrin LG, Zager M, Zhang J, Krenn G, McDermott R, Horse-Grant D, Silgard E, Colevas K, Shannon P, Bolouri H, Holland EC.

Nat Genet. 2018 Sep;50(9):1203-1204. doi: 10.1038/s41588-018-0208-7. No abstract available.

PMID:
30158685
15.

Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations.

Wang AC, Jones DTW, Abecassis IJ, Cole BL, Leary SES, Lockwood CM, Chavez L, Capper D, Korshunov A, Fallah A, Wang S, Ene C, Olson JM, Geyer JR, Holland EC, Lee A, Ellenbogen RG, Ojemann JG.

Mol Cancer Res. 2018 Oct;16(10):1491-1498. doi: 10.1158/1541-7786.MCR-17-0507. Epub 2018 Jul 13.

16.

Copy number profiling across glioblastoma populations has implications for clinical trial design.

Cimino PJ, McFerrin L, Wirsching HG, Arora S, Bolouri H, Rabadan R, Weller M, Holland EC.

Neuro Oncol. 2018 Sep 3;20(10):1368-1373. doi: 10.1093/neuonc/noy108.

17.

A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.

Ozawa T, Arora S, Szulzewsky F, Juric-Sekhar G, Miyajima Y, Bolouri H, Yasui Y, Barber J, Kupp R, Dalton J, Jones TS, Nakada M, Kumabe T, Ellison DW, Gilbertson RJ, Holland EC.

Cell Rep. 2018 Jun 26;23(13):3787-3797. doi: 10.1016/j.celrep.2018.04.099.

18.

Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.

Zhang F, Stephan SB, Ene CI, Smith TT, Holland EC, Stephan MT.

Cancer Res. 2018 Jul 1;78(13):3718-3730. doi: 10.1158/0008-5472.CAN-18-0306. Epub 2018 May 14.

19.

Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma.

Cimino PJ, Kim Y, Wu HJ, Alexander J, Wirsching HG, Szulzewsky F, Pitter K, Ozawa T, Wang J, Vazquez J, Arora S, Rabadan R, Levine R, Michor F, Holland EC.

Genes Dev. 2018 Apr 1;32(7-8):512-523. doi: 10.1101/gad.312157.118. Epub 2018 Apr 9.

20.

Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.

Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF.

Sci Rep. 2018 Jan 19;8(1):1180. doi: 10.1038/s41598-018-19451-6.

21.

Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.

Szulzewsky F, Schwendinger N, Güneykaya D, Cimino PJ, Hambardzumyan D, Synowitz M, Holland EC, Kettenmann H.

Neuro Oncol. 2018 Feb 19;20(3):355-366. doi: 10.1093/neuonc/nox165.

22.

Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion.

Pattwell SS, Holland EC.

Trends Mol Med. 2017 Sep;23(9):773-776. doi: 10.1016/j.molmed.2017.07.008. Epub 2017 Jul 31.

23.

Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.

Kievit FM, Wang K, Ozawa T, Tarudji AW, Silber JR, Holland EC, Ellenbogen RG, Zhang M.

Nanomedicine. 2017 Oct;13(7):2131-2139. doi: 10.1016/j.nano.2017.06.004. Epub 2017 Jun 11.

24.

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC.

Acta Neuropathol Commun. 2017 May 22;5(1):39. doi: 10.1186/s40478-017-0443-7.

25.

Mutant IDH1 regulates the tumor-associated immune system in gliomas.

Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, Margineantu DH, Rao A, Bolouri H, Delrow J, Hockenbery D, Houghton AM, Holland EC.

Genes Dev. 2017 Apr 15;31(8):774-786. doi: 10.1101/gad.294991.116. Epub 2017 May 2.

26.

Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer.

Connolly NP, Stokum JA, Schneider CS, Ozawa T, Xu S, Galisteo R, Castellani RJ, Kim AJ, Simard JM, Winkles JA, Holland EC, Woodworth GF.

PLoS One. 2017 Mar 30;12(3):e0174557. doi: 10.1371/journal.pone.0174557. eCollection 2017.

27.

Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels.

Weller M, Holland EC, Hambardzumyan D.

Brain. 2017 Mar 1;140(3):e17. doi: 10.1093/brain/aww325. No abstract available.

PMID:
28007996
28.

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD.

Acta Neuropathol. 2017 Jan;133(1):5-12. doi: 10.1007/s00401-016-1643-0. Epub 2016 Nov 17.

29.

Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression.

Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins JN, Kim Y, Lobo K, Persson AI, Reis GF, McKnight TR, Holland EC, Phillips JJ, Weaver VM.

Nat Cell Biol. 2016 Dec;18(12):1336-1345. doi: 10.1038/ncb3429. Epub 2016 Nov 7.

30.

ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells.

Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, Holland EC.

Sci Rep. 2016 Jul 26;6:25956. doi: 10.1038/srep25956.

31.

Human glioblastoma-associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples.

Szulzewsky F, Arora S, de Witte L, Ulas T, Markovic D, Schultze JL, Holland EC, Synowitz M, Wolf SA, Kettenmann H.

Glia. 2016 Aug;64(8):1416-36. doi: 10.1002/glia.23014.

PMID:
27312099
32.

High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe.

Huang R, Harmsen S, Samii JM, Karabeber H, Pitter KL, Holland EC, Kircher MF.

Theranostics. 2016 May 7;6(8):1075-84. doi: 10.7150/thno.13842. eCollection 2016.

33.

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.

Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC, Joyce JA.

Science. 2016 May 20;352(6288):aad3018. doi: 10.1126/science.aad3018.

34.

Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Lu F, Chen Y, Zhao C, Wang H, He D, Xu L, Wang J, He X, Deng Y, Lu EE, Liu X, Verma R, Bu H, Drissi R, Fouladi M, Stemmer-Rachamimov AO, Burns D, Xin M, Rubin JB, Bahassi EM, Canoll P, Holland EC, Lu QR.

Cancer Cell. 2016 May 9;29(5):669-683. doi: 10.1016/j.ccell.2016.03.027.

35.

Big data visualization identifies the multidimensional molecular landscape of human gliomas.

Bolouri H, Zhao LP, Holland EC.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5394-9. doi: 10.1073/pnas.1601591113. Epub 2016 Apr 26.

36.

Corticosteroids compromise survival in glioblastoma.

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D.

Brain. 2016 May;139(Pt 5):1458-71. doi: 10.1093/brain/aww046. Epub 2016 Mar 28.

37.

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.

Lemasson B, Wang H, Galbán S, Li Y, Zhu Y, Heist KA, Tsein C, Chenevert TL, Rehemtulla A, Galbán CJ, Holland EC, Ross BD.

Neoplasia. 2016 Feb;18(2):82-9. doi: 10.1016/j.neo.2015.11.014.

38.

Glioma Stem-like Cells Keep Their H3.3 Variant Levels at Bay.

Becher OJ, Holland EC.

Cancer Cell. 2015 Dec 14;28(6):679-680. doi: 10.1016/j.ccell.2015.12.001.

39.

The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes.

Xie Y, Bergström T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, Segerman A, Wicher G, Niklasson M, Baskaran S, Sreedharan S, Everlien I, Kastemar M, Hermansson A, Elfineh L, Libard S, Holland EC, Hesselager G, Alafuzoff I, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L.

EBioMedicine. 2015 Aug 15;2(10):1351-63. doi: 10.1016/j.ebiom.2015.08.026. eCollection 2015 Oct.

40.

Optimization of radiation dosing schedules for proneural glioblastoma.

Badri H, Pitter K, Holland EC, Michor F, Leder K.

J Math Biol. 2016 Apr;72(5):1301-36. doi: 10.1007/s00285-015-0908-x. Epub 2015 Jun 21.

PMID:
26094055
41.

Image-Guided Tumor Resection.

Parrish-Novak J, Holland EC, Olson JM.

Cancer J. 2015 May-Jun;21(3):206-12. doi: 10.1097/PPO.0000000000000113. Review.

42.

Personalized medicine for gliomas.

Ene CI, Holland EC.

Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S89-95. doi: 10.4103/2152-7806.151351. eCollection 2015.

43.

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.

Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB.

Sci Transl Med. 2015 Feb 11;7(274):274ra17. doi: 10.1126/scitranslmed.aaa1009.

44.

Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging.

Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spaliviero M, White JR, Monette S, O'Connor R, Pitter KL, Sastra SA, Saborowski M, Holland EC, Singer S, Olive KP, Lowe SW, Blasberg RG, Kircher MF.

Sci Transl Med. 2015 Jan 21;7(271):271ra7. doi: 10.1126/scitranslmed.3010633.

45.

Rethinking glioma treatment strategy.

Ozawa T, Holland EC.

Oncotarget. 2014 Oct 30;5(20):9532-3. No abstract available.

46.

Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells.

Lindberg N, Jiang Y, Xie Y, Bolouri H, Kastemar M, Olofsson T, Holland EC, Uhrbom L.

J Neurosci. 2014 Oct 29;34(44):14644-51. doi: 10.1523/JNEUROSCI.2977-14.2014.

47.

Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.

Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC.

Cancer Cell. 2014 Aug 11;26(2):288-300. doi: 10.1016/j.ccr.2014.06.005.

48.

Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner.

Karabeber H, Huang R, Iacono P, Samii JM, Pitter K, Holland EC, Kircher MF.

ACS Nano. 2014 Oct 28;8(10):9755-66. doi: 10.1021/nn503948b. Epub 2014 Aug 22.

49.

Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma.

Becher OJ, Holland EC.

EMBO J. 2014 Sep 17;33(18):1984-6. doi: 10.15252/embj.201489479. Epub 2014 Jul 24.

50.

The SHH/Gli pathway is reactivated in reactive glia and drives proliferation in response to neurodegeneration-induced lesions.

Pitter KL, Tamagno I, Feng X, Ghosal K, Amankulor N, Holland EC, Hambardzumyan D.

Glia. 2014 Oct;62(10):1595-607. doi: 10.1002/glia.22702. Epub 2014 Jun 4.

Supplemental Content

Loading ...
Support Center